You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Austin, Texas-based molecular diagnostics firm logged $60.6 million in Q3 revenues as its system sales shot up 26 percent to $9.6 million.
The Australian firm provided an update on its in vitro diagnostics business, noting that it has also rebranded its core technologies and continues to license them.
The firm plans to officially launch and introduce the PCR-based platform and herpes assay over the next several weeks.
Focus Diagnostics' Simplexa Direct test for herpes simplex viruses 1 & 2 was its first molecular test for the viruses and seventh overall to get FDA clearance.
Meridian's Diagnostics segment grew 2 percent lifted by a 10 percent increase in revenues from the illumigene molecular product line.
The firm expects to receive both FDA clearance and CE-IVD marking for the system and assay by the end of 2015 and has more assays in development.
The new assay expands the sexually transmitted infection menu for the cobas 4800 to three tests.
The firm is pursuing CE-IVD clearance of the new platform populated with a menu of its MGB assays.
The assays use specimens from symptomatic patients for the qualitative detection and differentiation of HSV-1 and HSV-2 with results generated within one hour.
The presentations were part of a Quidel-sponsored workshop and poster sessions at the Clinical Virology Symposium in Daytona Beach, Fla.
The Atlantic reports another SARS-CoV-2 testing problem may be lurking: backlogs.
Researchers have sequenced the genome of "the Methuselah of freshwater fish."
The US Biomedical Advanced Research and Development Authority is supporting efforts to develop vaccines against SARS-CoV-2.
In Genome Biology this week: difference in methylation in neurons from Parkinson's disease patients, differential expression analysis by barcoded sequencing approach, and more.